Vanda Pharmaceuticals Inc. (VNDA) News
Filter VNDA News Items
VNDA News Results
|Loading, please wait...|
VNDA News Highlights
- VNDA's 30 day story count now stands at 2.
- Over the past 23 days, the trend for VNDA's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
Latest VNDA News From Around the Web
Below are the latest news stories about VANDA PHARMACEUTICALS INC that investors may wish to consider to help them evaluate VNDA as an investment opportunity.
Vanda Pharmaceuticals Appoints Dr. Tage Honoré to its Board of Directors
Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the appointment of Tage Honoré, Ph.D., D.Sc. to its Board of Directors effective March 15, 2023. Following Dr. Honoré's appointment, Vanda's Board of Directors is now comprised of six directors, five of whom are independent.
Shareholders in Vanda Pharmaceuticals (NASDAQ:VNDA) are in the red if they invested five years ago
Statistically speaking, long term investing is a profitable endeavour. But unfortunately, some companies simply don't...
Why Vanda Pharmaceuticals Stock Crawled Higher Today
Earnings season seems to be the pill needed to improve sentiment on Vanda Pharmaceuticals (NASDAQ: VNDA). The commercial-stage biotech saw its share price rise by almost 1% on Thursday, following the release of quarterly results that comfortably topped analyst estimates. The sleep medication's sales were higher in the same period one year ago when it brought in $44 million.
Vanda Pharmaceuticals seeks multiple FDA approvals while battling generic competition
The D.C. drugmaker faces a threat to its top line as a competitor starts selling a generic version of its chief product.
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Q4 2022 Earnings Call Transcript
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Q4 2022 Earnings Call Transcript February 8, 2023 Operator: Ladies and gentlemen, thank you for standing by, and welcome to the Q4 2022 Vanda Pharmaceuticals Inc. Earnings Conference Call. I would now like to turn the call over to Kevin Moran, Vanda’s Chief Financial Officer. Please go ahead. Kevin Moran: Thank […]
Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results
Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the fourth quarter and full year ended December 31, 2022.
Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2022 Financial Results on February 8, 2023
Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the fourth quarter and full year 2022 on Wednesday, February 8, 2023, after the market closes.
Are Vanda Pharmaceuticals Inc.'s (NASDAQ:VNDA) Fundamentals Good Enough to Warrant Buying Given The Stock's Recent Weakness?
It is hard to get excited after looking at Vanda Pharmaceuticals' (NASDAQ:VNDA) recent performance, when its stock has...
Vanda Pharmaceuticals Announces Participation in the J.P. Morgan Healthcare Conference
Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate in the J.P. Morgan Healthcare Conference in San Francisco, California on Thursday, January 12, 2023. A corporate presentation is scheduled for 12:00 p.m. Pacific Time (3:00 p.m. Eastern Time).
Vanda Pharmaceuticals says its schizophrenia drug works in bipolar disorder
“We believe this is really critical data to ask for an FDA approval,” said Vanda’s president and CEO.